Financial reports
10-K
2023 FY
Annual report
15 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
13 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
8 Apr 22
NT 10-K
Notice of late annual filing
1 Apr 22
Current reports
8-K
Submission of Matters to a Vote of Security Holders
25 Apr 24
8-K/A
Other Events
3 Apr 24
8-K
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
26 Mar 24
8-K
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
15 Mar 24
8-K
Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
23 Feb 24
8-K
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
20 Feb 24
8-K
Other Events
12 Feb 24
8-K
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for AmeluzĀ® to Permit Up to Three Tubes per Use
5 Feb 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Jan 24
Registration and prospectus
S-1/A
IPO registration (amended)
19 Mar 24
S-1
IPO registration
8 Mar 24
D
$8.00 mm in equity / options / securities to be acquired, sold $8.00 mm, 8 investors
5 Mar 24
RW
Registration withdrawal request
20 Feb 24
S-1/A
IPO registration (amended)
29 Jan 24
S-1
IPO registration
16 Jan 24
424B4
Prospectus supplement with pricing info
1 Nov 23
S-1/A
IPO registration (amended)
26 Oct 23
S-1/A
IPO registration (amended)
13 Oct 23
S-1
IPO registration
4 Oct 23
Proxies
DEF 14A
Definitive proxy
17 Apr 24
DEF 14A
Definitive proxy
20 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
DEF 14A
Definitive proxy
17 Nov 23
DEF 14A
Definitive proxy
21 Apr 23
PRE 14A
Preliminary proxy
11 Apr 23
DEFA14A
Additional proxy soliciting materials
8 Dec 22
DEFA14A
Additional proxy soliciting materials
29 Nov 22
DEFA14A
Additional proxy soliciting materials
21 Nov 22
DEFR14A
Revised proxy
10 Nov 22
Other
EFFECT
Notice of effectiveness
23 Apr 24
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
CORRESP
Correspondence with SEC
13 Oct 23
UPLOAD
Letter from SEC
11 Oct 23
EFFECT
Notice of effectiveness
8 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
UPLOAD
Letter from SEC
30 Aug 22
EFFECT
Notice of effectiveness
14 Jun 22
EFFECT
Notice of effectiveness
10 Jun 22
Ownership
SC 13G
Rosalind Advisors, Inc.
21 Mar 24
SC 13G
Rosalind Advisors, Inc.
20 Mar 24
SC 13G
LYTTON LAURENCE W
20 Mar 24
SC 13G
HIRSCHMAN ORIN
20 Mar 24
SC 13G
Bigger Capital, LLC
15 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
Heikki Lanckriet
22 Aug 23
4
Erica L. Monaco
22 May 23
4
Hermann Luebbert
22 May 23
4
Eugene Frederick Leffler
12 Jan 23